The drugs that transformed diabetes and weight-loss treatment may have a far wider reach than anyone expected. A large new study suggests the popular class of medications known as GLP-1 drugs could help address one of society’s most stubborn challenges: addiction.
A massive study of more than 600,000 U.S. veterans suggests popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss; they could also help fight addiction itself, with the research linking the drugs to lower risks of addiction and overdose. The finding adds compelling weight to a growing body of evidence that these medications act on the brain’s reward circuitry in ways that extend well beyond appetite.
That mechanism is becoming clearer through related research. Scientists have been working to understand both how these drugs work and why their effects sometimes plateau, and the emerging picture points to deep-brain reward pathways as central to their action. The implication that a single class of drugs might address overeating, substance use, and compulsive behavior through a shared biological pathway has made GLP-1 medications one of the most closely watched areas in medicine. The innovation isn’t slowing down. Researchers have developed an experimental diabetes and obesity pill that works in a completely different way from existing drugs — rather than reducing hunger, it activates metabolism in skeletal muscle to help lower blood sugar and increase fat burning. Such an approach could potentially help patients who don’t tolerate appetite-suppressing drugs well.
The week’s research underscored how much diet and metabolism science is advancing on multiple fronts. A study tracking more than 205,000 people for nearly 40 years found that eating three servings of fries per week was linked to a 20% higher risk of developing type 2 diabetes, while baked, boiled, or mashed potatoes showed no significant increase, and swapping potatoes for whole grains lowered risk. The distinction highlights how preparation method, not just the food itself, can shape health outcomes.
Cancer research also delivered notable progress. In a melanoma vaccine trial, nearly 70% of patients receiving the vaccine were cancer-free after five years, compared to 49% in the standard treatment group, with a larger phase 3 trial now underway. Separately, scientists reported cracking an “undruggable” pancreatic cancer target and nearly doubling survival in one of the most lethal cancers.
For the millions who take GLP-1 drugs, the addiction findings offer an intriguing glimpse of how a medication developed for metabolic disease might ripple outward into entirely different areas of health. As always, larger and longer trials will be needed to confirm the effects but the direction of the research is opening doors that few anticipated even a couple of years ago.
This article summarizes published research for general information and is not medical advice. Consult a healthcare professional before starting or changing any medication.